OnKure Therapeutics, Inc. SEC filings OKUR
OnKure Therapeutics, Inc. has 404 filings in SEC EDGAR's recent list, going back to Jan 8, 2018. Its latest annual report, Form ARS, was filed on Apr 21, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 13, 2026 | Aug 7, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 4, 2026 | Jun 3, 2026 |
| 8-K |
Current report
Results of operations
|
May 5, 2026 | May 5, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Other events
|
Mar 30, 2026 | Mar 27, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 12, 2026 | Mar 12, 2026 |
| 8-K |
Current report
Material agreement
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2025 | Aug 12, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 26, 2025 | Jun 26, 2025 |
| 8-K |
Current report
Shareholder vote results
|
May 28, 2025 | May 27, 2025 |
| 8-K |
Current report
Results of operations
|
May 6, 2025 | May 6, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 10, 2025 | Mar 10, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 10, 2024 | Dec 10, 2024 |
| 8-K |
Current report
Auditor change, Other events
|
Nov 7, 2024 | Nov 7, 2024 |
| 8-K |
Current report
Acquisition or sale of assets, Unregistered share sale, Change to shareholder rights, Change in control, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Oct 8, 2024 | Oct 4, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Oct 2, 2024 | Sep 26, 2024 |
| 8-K |
Current report
Other events
|
Sep 20, 2024 | Sep 20, 2024 |
| 8-K |
Current report
Officer or director change
|
Sep 13, 2024 | Sep 9, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2024 | Aug 13, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change in control, Officer or director change, Regulation FD disclosure
|
May 13, 2024 | May 10, 2024 |
| 8-K |
Current report
Results of operations
|
May 7, 2024 | May 7, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 28, 2024 | Mar 28, 2024 |
| 8-K |
Current report
Exit or restructuring costs
|
Feb 23, 2024 | Feb 20, 2024 |
| 8-K |
Current report
Exit or restructuring costs, Other events
|
Dec 14, 2023 | Dec 14, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2023 | Nov 13, 2023 |
| 8-K |
Current report
Other events
|
Oct 30, 2023 | Oct 30, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 10, 2023 | Oct 9, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 7, 2023 | Jun 6, 2023 |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
May 5, 2023 | May 5, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
May 3, 2023 | May 3, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 27, 2023 | Mar 27, 2023 |
| 8-K |
Current report
Other events
|
Mar 14, 2023 | Mar 14, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 10, 2023 | Mar 10, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 9, 2023 | Jan 9, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 8, 2022 | Nov 8, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 9, 2022 | Aug 9, 2022 |
| 8-K |
Current report
Officer or director change
|
Aug 2, 2022 | Aug 2, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 2, 2022 | Jun 1, 2022 |
| 8-K |
Current report
Results of operations
|
May 10, 2022 | May 10, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 23, 2022 | Mar 23, 2022 |
| 8-K |
Current report
Officer or director change
|
Mar 7, 2022 | Mar 2, 2022 |
| 8-K |
Current report
Officer or director change
|
Feb 2, 2022 | Feb 2, 2022 |
| 8-K |
Current report
Officer or director change
|
Jan 24, 2022 | Jan 18, 2022 |
| 8-K |
Current report
Officer or director change
|
Dec 27, 2021 | Dec 23, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2021 | Nov 11, 2021 |
| 8-K |
Current report
Officer or director change
|
Oct 12, 2021 | Oct 11, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 11, 2021 | Aug 11, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2021 | Aug 11, 2021 |
| 8-K |
Current report
Results of operations
|
May 20, 2021 | May 20, 2021 |
| 8-K |
Current report
Officer or director change
|
May 14, 2021 | May 11, 2021 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Apr 13, 2021 | Apr 13, 2021 |
Showing 55 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OKUR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boulder, CO
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1637715
- Former names
- Reneo Pharmaceuticals, Inc. (until Oct 2, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.